Portal de Periódicos da CAPES

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

2014; Elsevier BV; Volume: 124; Issue: 25 Linguagem: Inglês

10.1182/blood-2014-07-587477

1528-0020

Christopher G. Kanakry, Hua-Ling Tsai, Javier Bolaños‐Meade, B. Douglas Smith, Ivana Gojo, Jennifer A. Kanakry, Yvette L. Kasamon, Douglas E. Gladstone, William Matsui, Ivan Borrello, Carol Ann Huff, Lode J. Swinnen, Jonathan D. Powell, Keith W. Pratz, Amy E. DeZern, Margaret M. Showel, Michael A. McDevitt, Robert A. Brodsky, Mark J. Levis, Richard F. Ambinder, Ephraim J. Fuchs, Gary L. Rosner, Richard J. Jones, Leo Luznik,

Acute Lymphoblastic Leukemia research

Key Points Posttransplantation cyclophosphamide is effective as sole GVHD prophylaxis for myeloablative HLA-matched–related or –unrelated BMT. Despite low chronic GVHD with PTCy, relapse and survival are comparable with outcomes reported using other GVHD prophylactic approaches.